VShe project, launched under the partnership agreement signed between the CHU Ibn Sina and the Novo Nordisk Pharma laboratories on April 16, 2021, is part of the strategy of the Ministry of Health and Social Protection, which provides in line 23 of its national Health 2025 plan, the establishment of an integrated national health data system.
Set up within the oncology department of the children’s hospital and the emergency care unit of the CHU Ibn Sina in Rabat, this project aims to provide information relating to the medical management of haemophilia and other constitutional haemorrhagic diseases, and makes it possible to trace the progress of the national plans implemented.
This electronic database is structured around two main axes: the establishment of an information system to collect and share information on hemophilia, and the production of educational audiovisual material on hemophilia, usable on several media (television, smartphones, internet, etc.).
100% Moroccan program
In this regard, a pilot version of the information program for the care of hemophilia patients, entirely developed in Morocco, was developed in accordance with the recommendations issued by Moroccan experts in the field at the CHU Ibn Sina in Rabat.
On this occasion, the director of the CHU Ibn Sina in Rabat, Professor Abdelkader Roukani, indicated in a statement to the press that the number of hemophiliac patients in Morocco, children and adults, is estimated at around 3,000 cases, noting that this disease causes bleeding “because the infected person lacks the materials to prevent them”.
He added that the launch of the database will make it possible to list patients suffering from hemophilia, and the organization of the journey of the patient suffering from this disease with a view to ensuring hospitalization and medication, stressing that in If severe symptoms develop, patients can be managed within a regulated framework to protect them from the serious consequences that result from the haemorrhage.
For his part, the professor of pediatric hematology-oncology at the hemophilia treatment center at the Children’s Hospital at the CHU Ibn Sina in Rabat, Mohamed El Khorassani, stressed that the patient with this disease must follow a educational and awareness program on how to interact with this disease and how to cure it, noting that the drug is currently available in Morocco, but its cost is high.
Hemophilia is a serious hereditary disease, resulting in the impossibility for the blood to clot. There are two predominant types of hemophilia, hemophilia A is the most common, it is characterized by a deficiency of coagulation factor VIII. Hemophilia B, five times rarer, is linked to a deficiency of coagulation factor IX.